Usefulness of McRAPD for typing and importance of biofilm production in a case of nosocomial ventriculoperitoneal shunt infection caused by Candida lusitaniae
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem
- MeSH
- antifungální látky farmakologie MeSH
- astrocytom mozkomíšní mok komplikace farmakoterapie mikrobiologie patologie chirurgie MeSH
- biofilmy účinky léků růst a vývoj MeSH
- Candida účinky léků genetika izolace a purifikace MeSH
- denaturace nukleových kyselin MeSH
- dítě MeSH
- hydrocefalus mozkomíšní mok komplikace farmakoterapie mikrobiologie patologie chirurgie MeSH
- infekce spojené se zdravotní péčí mozkomíšní mok komplikace farmakoterapie mikrobiologie patologie chirurgie MeSH
- kandidóza mozkomíšní mok komplikace farmakoterapie mikrobiologie patologie chirurgie MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- mykologické určovací techniky MeSH
- nádory mozku mozkomíšní mok komplikace farmakoterapie mikrobiologie patologie chirurgie MeSH
- pulzní gelová elektroforéza MeSH
- technika náhodné amplifikace polymorfní DNA * MeSH
- terapie neúspěšná MeSH
- ventrikuloperitoneální zkrat škodlivé účinky MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antifungální látky MeSH
A case report of ventriculoperitoneal shunt infection caused by Candida lusitaniae in a 6-year-old patient with cerebral astrocytoma and obstructive hydrocephalus is presented briefly with emphasis on the course of antifungal treatment. Seven isolates recovered subsequently from the cerebrospinal fluid were studied retrospectively. To confirm identity, isolates were typed using pulsed-field gel electrophoresis and melting curve of random amplified polymorphic DNA (McRAPD). Further, the ability to form biofilm and its susceptibility to systemic antifungals were evaluated. Using McRAPD, identity of C. lusitaniae isolates showing slight microevolutionary changes in karyotypes was undoubtedly confirmed; successful application of numerical interpretation of McRAPD for typing is demonstrated here for the first time. The strain was also recognized as a strong biofilm producer. Moreover, minimum biofilm inhibitory concentrations were very high, in contrast to low antifungal minimum inhibitory concentrations of isolates. It can be concluded that McRAPD seems to be a simple and reliable method not only for identification but also for typing of yeasts. A ventriculoperitoneal shunt colonized by C. lusitaniae was revealed as the source of this nosocomial infection, and the ability of the strain to form biofilm on its surface likely caused treatment failure.
Zobrazit více v PubMed
Infect Immun. 2002 Feb;70(2):878-88 PubMed
J Clin Microbiol. 1992 Nov;30(11):3005-8 PubMed
Infect Dis Obstet Gynecol. 2001;9(4):245-7 PubMed
Drugs. 2009;69 Suppl 1:33-8 PubMed
Pediatr Infect Dis J. 1992 Oct;11(10):878-80 PubMed
J Clin Microbiol. 1997 Aug;35(8):2031-9 PubMed
Pediatr Infect Dis J. 1988 May;7(5):368-9 PubMed
Clin Microbiol Rev. 1995 Oct;8(4):462-78 PubMed
J Clin Microbiol. 2007 Jun;45(6):1843-50 PubMed
Ann Trop Med Parasitol. 2010 Jul;104(5):427-37 PubMed
Clin Infect Dis. 2001 May 1;32(9):1249-72 PubMed
Clin Microbiol Infect. 2001 Jul;7(7):379-82 PubMed
Antimicrob Agents Chemother. 2002 Nov;46(11):3591-6 PubMed
Clin Microbiol Rev. 2000 Apr;13(2):332-70 PubMed
Pediatr Infect Dis J. 1987 Aug;6(8):758-9 PubMed
FEMS Yeast Res. 2006 Nov;6(7):979-86 PubMed
J Clin Microbiol. 1992 Feb;30(2):449-54 PubMed
Postgrad Med J. 1993 Nov;69(817):878-80 PubMed
Pediatr Infect Dis J. 2006 Aug;25(8):758-9 PubMed
Antimicrob Agents Chemother. 2001 Sep;45(9):2475-9 PubMed
J Microbiol Methods. 2005 Jan;60(1):107-13 PubMed
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Sep;155(3):239-52 PubMed
Yeast. 2001 Aug;18(11):1035-46 PubMed
Diagn Microbiol Infect Dis. 2008 May;61(1):61-3 PubMed
J Clin Microbiol. 1995 Jun;33(6):1467-70 PubMed
Scand J Infect Dis. 1998;30(5):485-7 PubMed
J Infect Chemother. 2001 Mar;7(1):45-8 PubMed
Res Microbiol. 2011 May;162(4):386-92 PubMed
Diagn Microbiol Infect Dis. 2003 Sep;47(1):331-9 PubMed
Clin Infect Dis. 2003 Jan 15;36(2):e14-8 PubMed
Eur J Clin Microbiol Infect Dis. 2002 Apr;21(4):294-9 PubMed
J Clin Microbiol. 1979 Aug;10(2):202-5 PubMed
J Hosp Infect. 2001 Sep;49(1):37-42 PubMed
Folia Microbiol (Praha). 2007;52(3):209-14 PubMed
BMC Microbiol. 2009 Nov 10;9:234 PubMed
Antimicrob Agents Chemother. 2002 Jun;46(6):1773-80 PubMed
Diagn Microbiol Infect Dis. 1994 Nov;20(3):127-33 PubMed
J Med Case Rep. 2009 May 14;3:7611 PubMed
Mycoses. 2002 Apr;45(3-4):120-2 PubMed
Infect Control Hosp Epidemiol. 1998 May;19(5):343-5 PubMed
Ugeskr Laeger. 1990 Feb 26;152(9):611-2 PubMed
Bioinformatics. 2000 Nov;16(11):1056-8 PubMed
Microbiology (Reading). 2003 Feb;149(Pt 2):353-362 PubMed
FEMS Immunol Med Microbiol. 1999 Jan;23(1):75-8 PubMed
Jpn J Infect Dis. 2008 Mar;61(2):138-9 PubMed
FEMS Microbiol Lett. 1996 Nov 15;145(1):23-6 PubMed
Smoothie Drinks: Possible Source of Resistant and Biofilm-Forming Microorganisms
